OBJECTIVE: To assess the value of the 28-joint Disease Activity Score (DAS28) in evaluating disease activity in rheumatoid arthritis (RA) associated with fibromyalgia (FM). In this situation, because of the weight of the subjective measures included in the DAS28 equation, the patient's status may be overestimated, leading to inappropriate treatment. We analyze the relationship between RA and FM and discuss whether the association is random or a marker of poor prognosis. METHODS: A questionnaire, developed when biologic therapies were introduced, was administered and the results analyzed in a consecutive, female outpatient population including 105 patients with RA, 49 with RA and FM (RAF), and 28 with FM. Psychosocial characteristics, disease presentation, and radiographic joint destruction evaluation were compared in the 3 populations. RESULTS: The presentation of RA was the same in patients with RA and RAF, but the 2 populations differed by socioprofessional characteristics, significantly higher disease activity in patients with RAF, and significantly more severe joint destruction in patients with RA. The RAF group was similar to the FM control population in socioprofessional and some physical characteristics. Regression analysis using the DAS28 measures differed significantly in the weight allowed to 28-joint counts for pain and swelling, but the constant factor was higher in patients with RAF. CONCLUSION: DAS28 overestimated objective RA severity in patients who also had FM. The association between RA and FM does not appear to be a marker of worse prognosis, but rather a fortuitous association between the 2 diseases and one that may afford these patients some protection against joint destruction.
OBJECTIVE: To assess the value of the 28-joint Disease Activity Score (DAS28) in evaluating disease activity in rheumatoid arthritis (RA) associated with fibromyalgia (FM). In this situation, because of the weight of the subjective measures included in the DAS28 equation, the patient's status may be overestimated, leading to inappropriate treatment. We analyze the relationship between RA and FM and discuss whether the association is random or a marker of poor prognosis. METHODS: A questionnaire, developed when biologic therapies were introduced, was administered and the results analyzed in a consecutive, female outpatient population including 105 patients with RA, 49 with RA and FM (RAF), and 28 with FM. Psychosocial characteristics, disease presentation, and radiographic joint destruction evaluation were compared in the 3 populations. RESULTS: The presentation of RA was the same in patients with RA and RAF, but the 2 populations differed by socioprofessional characteristics, significantly higher disease activity in patients with RAF, and significantly more severe joint destruction in patients with RA. The RAF group was similar to the FM control population in socioprofessional and some physical characteristics. Regression analysis using the DAS28 measures differed significantly in the weight allowed to 28-joint counts for pain and swelling, but the constant factor was higher in patients with RAF. CONCLUSION: DAS28 overestimated objective RA severity in patients who also had FM. The association between RA and FM does not appear to be a marker of worse prognosis, but rather a fortuitous association between the 2 diseases and one that may afford these patients some protection against joint destruction.
Authors: W Häuser; S Schild; M Kosseva; S Hayo; H von Wilmowski; R Alten; J Langhorst; W Hofmann; J Maus; H Glaesmer Journal: Schmerz Date: 2010-06 Impact factor: 1.107
Authors: Estíbaliz Loza; Cristina Lajas; Jose Luis Andreu; Alejandro Balsa; Isidoro González-Álvaro; Oscar Illera; Juan Ángel Jover; Isabel Mateo; Javier Orte; Javier Rivera; José Manuel Rodríguez Heredia; Fredeswinda Romero; Juan Antonio Martínez-López; Ana María Ortiz; Esther Toledano; Virginia Villaverde; Loreto Carmona; Santos Castañeda Journal: Rheumatol Int Date: 2014-12-28 Impact factor: 2.631
Authors: Yvonne C Lee; Clifton O Bingham; Robert R Edwards; Wendy Marder; Kristine Phillips; Marcy B Bolster; Daniel J Clauw; Larry W Moreland; Bing Lu; Alyssa Wohlfahrt; Zhi Zhang; Tuhina Neogi Journal: Arthritis Care Res (Hoboken) Date: 2018-02 Impact factor: 4.794
Authors: H Singh; V Gupta; S Ray; H Kumar; P Talapatra; M Kaur; S Kumar; S Arya; R Mathur; N Ghangas Journal: Clin Rheumatol Date: 2012-09-15 Impact factor: 2.980